IP Library Granted Patent US 10,821,124
Granted Patent B2
US 10,821,124 · App. 15/554,738 · Granted Nov 3, 2020

Compositions for use in improving stool consistency or frequency in infants or young children

Inventors: Norbert Sprenger (Savigny, CH); Dominique Brassart (Chavannes-pres-Renens, CH); Delphine Egli (La Tour-de-Peilz, CH)
Assignee: Societe des Produits Nestle S.A.
A61K31/702A23L33/125A23L33/135A23L33/21A23L33/40A61K9/0056A61K35/741A61P1/00A23V2002/00A61K2035/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,821,124
App. No.
15/554,738
Granted
Nov 3, 2020
Kind
B2
Abstract

The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide for use in preventing and/or treating constipation and/or in improving stool consistency/frequency in an infant or a young child.

Claims (19)

1. A method for treating constipation in an infant or a young child in need thereof, the method comprising

administering a nutritional composition comprising human milk oligosaccharides (HMOs) comprising at least one fucosylated oligosaccharide to the infant or young child,

wherein the HMOs are the only oligosaccharides in the nutritional composition, the nutritional composition does not contain non-HMO polysaccharides or non-HMO oligosaccharides, and the nutritional composition does not contain any sialylated oligosaccharide,

the at least one fucosylated oligosaccharide is in a total amount of 1-1.25 g/L of the nutritional composition and/or in a total amount of 0.69-0.87 g/100 g of the nutritional composition on a dry weight basis, and

the nutritional composition is selected from the group consisting of an infant formula, a starter infant formula, a follow-on infant formula, a follow-up infant formula, a fortifier and a supplement.

2. A method for treating hard stool in an infant or a young child in need thereof, the method comprising

administering a nutritional composition comprising human milk oligosaccharides (HMOs) comprising at least one fucosylated oligosaccharide,

wherein the HMOs are the only oligosaccharides in the nutritional composition, the nutritional composition does not contain non-HMO polysaccharides or non-HMO oligosaccharides, and the nutritional composition does not contain any sialylated oligosaccharide,

the at least one fucosylated oligosaccharide is in a total amount of 1-1.25 g/L of the nutritional composition and/or in a total amount of 0.69-0.87 g/100 g of the nutritional composition on a dry weight basis to the infant or young child in need of same, and

the nutritional composition is selected from the group consisting of an infant formula, a starter infant formula, a follow-on infant formula, a follow-up infant formula, a fortifier and a supplement.

3. The method according to claim 1 wherein the at least one fucosylated oligosaccharide is selected from the group consisting of 2′-fucosyllactose, 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-fucohexaose, lacto-N-difucohexaose I, fucosyllacto-N-hexaose, fucosyllacto-N-neohexaose I, fucosyllacto-N-neohexaose II, difucosyllacto-N-hexaose I, difucosyllacto-N-neohexaose I, difucosyllacto-N-neohexaose II, fucosyl-para-Lacto-N-hexaose, and any combination thereof.

4. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide comprises a 2′ fucosyl-epitope.

5. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide is 2′-fucosyllactose (2′FL).

6. The method according to claim 1 , wherein the composition further comprising at least one probiotic microorganism.

7. The method according to claim 1 , wherein the composition does not comprise any N-acetylated oligosaccharides.

8. The method according to claim 2 , wherein the at least one fucosylated oligosaccharide is selected from the group consisting of 2′-fucosyllactose, 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-fucohexaose, lacto-N-difucohexaose I, fucosyllacto-N-hexaose, fucosyllacto-N-neohexaose I, fucosyllacto-N-neohexaose II, difucosyllacto-N-hexaose I, difucosyllacto-N-neohexaose I, difucosyllacto-N-neohexaose II, fucosyl-para-Lacto-N-hexaose, and any combination thereof.

9. The method according to claim 2 , wherein the at least one fucosylated oligosaccharide is 2′-fucosyllactose (2′FL).

10. The method according to claim 2 , wherein the composition further comprising at least one probiotic microorganism.

11. The method according to claim 2 , wherein the composition does not comprise any N-acetylated oligosaccharides.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2017
From: SPRENGER, NORBERT; BRASSART, DOMINIQUE; EGLI, DELPHINE
To: NESTEC S.A.
Reel/Frame 043666/0423 →
Priority Claims (1)
EP 15157724 · Mar 5, 2015 · regional
Continuity (1)
Related Publication 20180078573A1 · Mar 22, 2018